I think OCRX has a fair—but not great—chance of persuading the FDA to endorse advancing OCR-002 to phase-3, I agree and that is why I exited my position on the pop a month ago on the STOP-HE data update. Fair chance doesn't cut it anymore for me.. Buyout might be possible..